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Summary
Cost-eﬀectiveness acceptability curves (CEACs) have been widely adopted as a method to quantify and graphically
represent uncertainty in economic evaluation studies of health-care technologies. However, there remain some
common fallacies regarding the nature and shape of CEACs that largely result from the ‘textbook’ illustration of the
CEAC. This ‘textbook’ CEAC shows a smooth curve starting at probability 0, with an asymptote to 1 for higher
money values of the health outcome (l). But this familiar ‘ogive’ shape which makes the ‘textbook’ CEAC look like a
cumulative distribution function is just one special case of the CEAC. The reality is that the CEAC can take many
shapes and turns because it is a graphic transformation from the cost-eﬀectiveness plane, where the joint density of
incremental costs and eﬀects may ‘straddle’ quadrants with attendant discontinuities and asymptotes. In fact
CEACs: (i) do not have to cut the y-axis at 0; (ii) do not have to asymptote to 1; (iii) are not always monotonically
increasing in l; and (iv) do not represent cumulative distribution functions (cdfs). Within this paper we present a
‘gallery’ of CEACs in order to identify the fallacies and illustrate the facts surrounding the CEAC. The aim of the
paper is to serve as a reference tool to accompany the increased use of CEACs within major medical
journals. Copyright
Introduction
The technique of representing uncertainty in cost-
eﬀectiveness analysis through the use of cost-
eﬀectiveness acceptability curves (CEACs) has
been widely adopted as a method to quantify
and graphically represent uncertainty in economic
evaluation studies of health-care technologies.
CEACs can now be found in major medical
journals such as BMJ [1–5], New England Journal
of Medicine [6,7], Lancet [8], Circulation [9], Chest
[10] as well as health economics and health
technology assessment journals [11–17]. Given
the widespread dissemination of this technique it
is important to ensure that both analysts and
potential users of the information understand the
nature and interpretation of these curves. This
paper examines a variety of cost-eﬀectiveness
scenarios, presented on the cost-eﬀectiveness
plane, and presents a ‘gallery’ of CEACs with
associated explanations. The paper aims to identi-
fy the facts, dispel the fallacies and thus address
the frequently asked questions about CEACs. The
goal of the paper is to confront the confusion
surrounding the interpretation of the curves and
provide a useful reference tool to accompany the
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dispersion of CEACs within the economic evalua-
tion literature.
First, we provide an introduction to CEACs,
including a recap of the various methods for their
construction. Next, we list of the common fallacies
and present the facts about CEACs. Various cost-
eﬀectiveness scenarios are then examined and these
facts illustrated through a ‘gallery’ of CEACs.
Finally, some additional issues regarding the
interpretation and use of CEACs are discussed
and simple rules to aid interpretation are developed.
De¢nition of the CEACS
CEACs were originally introduced to represent the
uncertainty concerning the cost-eﬀectiveness of a
health-care intervention in the context of decisions
involving two interventions, as an alternative to
conﬁdence intervals around ICERs [18]. The
CEAC is derived from the joint density of
incremental costs (DC) and incremental eﬀects
(DE) for the intervention of interest, and repre-
sents the proportion of the density where the
intervention is cost-eﬀective for a range of values
of l. Parametric estimation is possible by assuming
a parametric functional form for the joint density
(DC,DE) (for example, the joint normal distribu-
tion assumed by Van Hout [18]). The CEAC is
then either determined directly by integrating the
joint density [18–20] or estimated indirectly via
parametric bootstrapping of the distribution [18].
Alternatively, the joint density can be generated by
non-parametric bootstrapping [21,22], when pa-
tient level data are available for re-sampling, or by
Monte Carlo simulation [23]. Where bootstrap-
ping or Monte Carlo simulation is employed, the
CEAC is determined as the proportion of the
(DC,DE) points where the intervention is cost-
eﬀective [21]. Where the joint density (DC,DE) is
plotted on the incremental cost-eﬀectiveness plane
[24], this proportion is easily identiﬁable as the
proportion falling to the southeast of a ray
through the origin with slope equal to l.
CEACS ^ the facts and fallacies
Fallacies about CEACs
The ‘textbook’ illustration of the CEAC shows a
smooth curve starting at probability zero with an
asymptote to 1, as we consider higher money
values for a health outcome (l). However, this
familiar ‘ogive’ shape represents just one of the
possible shapes that CEACs can take. This typical
example, which results from the scenario where the
entire joint density (DC,DE) is contained within
the northeast quadrant (where the intervention is
both more costly and more eﬀective), is largely
responsible for the common fallacies regarding the
shape and nature of CEACs:
(i) CEACs always cut the y-axis at 0;
(ii) CEACs always asymptote to 1;
(iii) CEACs are monotonically increasing in l and
(iv) CEACs represent cumulative distribution
functions.
Facts about CEACs
The reality is that the CEAC can take many shapes
and turns because it is a graphic transformation
from the cost-eﬀectiveness plane, where the joint
density of incremental costs and eﬀects (DC,DE)
may ‘straddle’ quadrants with attendant disconti-
nuities and asymptotes. Where there is a non-
negligible probability that the joint density extends
beyond the NE quadrant the CEAC will not have
the familiar shape:
(i) Do CEACs always cut the y-axis at 0?
In fact, by the deﬁnition of the x-axis, the point
where the CEAC intersects the y-axis represents
the position where the decision-maker is unwilling
to pay anything for health gains (l=0). Generat-
ing this point involves determining the proportion
of the joint density that involves cost-savings. If
there is any evidence that the intervention is less
costly, with any of the joint density (DC,DE)
falling into the SE or SW quadrants, the CEAC
will not intersect the y-axis at 0.
(ii) Do CEACs always asymptote to 1?
In fact, the value to which the CEAC asymp-
totes represents the position where the decision-
maker is willing to pay an inﬁnite amount for
additional units of health gain (e.g. QALYs).
Generating this point involves determining the
proportion of joint density that involves health
gains. If there is any evidence that the intervention
is less eﬀective, with any of the joint density
(DC,DE) falling into the SW or NW quadrants,
the CEAC will not asymptote to 1.
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(iii) Do CEACs increase monotonically in l?
In fact, the nature of the CEAC involves
including the joint density (DC,DE) that falls in
the NE quadrant (more costly, more eﬀective) as
cost-eﬀective, whilst simultaneously excluding the
joint density (DC,DE) that falls in the SW
quadrant (less costly, less eﬀective) as no longer
cost-eﬀective, as l (the value of the willingness to
trade between cost and eﬀect) increases. Hence, the
shape of the CEAC is entirely dependent upon the
location of the joint density (DC,DE) within the
CE plane.
(iv) Do CEACs represent a cumulative density
function?
Given facts (i) – (iii) CEACs cannot constitute
cumulative density functions (see Appendix A).
Cost-e¡ectiveness scenarios
Within this section we illustrate the facts through
examination of a series of cost-eﬀectiveness
scenarios (Figures 1, 4 and 5) and identiﬁcation
of the associated CEACs (Figures 2, 3 and 6). For
the purposes of illustration we assume a joint
normal distribution for (DC,DE), with a correla-
tion between cost and eﬀect of  0.5, and show
the uncertainty on the cost-eﬀectiveness plane
through ellipses of equal probability covering 5,
50 and 95% of the integrated joint density. In
keeping with the accepted standards for economic
evaluation [25] each scenario represents a sub-
group with a homogeneous treatment eﬀect. The
rules presented do not depend upon the assump-
tion of joint normality, and are applicable regard-
less of the method used to determine the joint
distribution (DC,DE). It should be noted that the
underlying descriptions relate to any density
occupying the quadrants discussed although the
particular level of the probabilities are speciﬁc to
the examples provided.
Joint density occupying a single quadrant
Ellipses A–D (Figure 1) represent scenarios
where there is a negligible probability that the
joint density (DC,DE) extends beyond a single
quadrant, the resulting CEACs are illustrated in
Figure 2.
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Figure 1. Nine cost-eﬀectiveness scenarios illustrated on the incremental cost-eﬀectiveness plane. Each ellipse represents 5, 50 and
95% of the joint distribution of cost and eﬀect. Each example involves a correlation of 0.5
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(A) The traditional ‘textbook’ case – the ellipse is
contained within the NE quadrant (more
costly, more eﬀective). The CEAC cuts the
y-axis at 0 because none of the density
involves cost-savings. The CEAC asymptotes
to 1 because the entire density involves health
gains. Hence, the CEAC is an increasing
function of l.
(B) The case of dominance – the ellipse is
contained within the SE quadrant (less costly,
more eﬀective). The CEAC cuts the y-axis at 1
because the entire density involves cost-
savings. The CEAC asymptotes to 1 because
the entire density involves health gains.
Hence, the CEAC forms a horizontal line at 1.
(C) The inverse of the traditional case – the ellipse
is contained within the SW quadrant (less
costly, less eﬀective). The CEAC cuts the y-
axis at 1 because the entire density involves
cost savings. The CEAC asymptotes to 0
because none of the density involves health
gains. Hence, the CEAC is a decreasing
function of l – this scenario and the resulting
CEAC is the inverse of the traditional case.a
(D) The dominated case – the ellipse is contained
within the NW quadrant (more costly and less
eﬀective). The CEAC cuts the y-axis at 0
because none of the density involves cost-
savings. The CEAC asymptotes to 0 because
none of the joint density involves health gains.
Hence, the CEAC forms a horizontal line at 0
– this scenario and the resulting CEAC is also
the inverse of the dominance case.
Joint density occupying 2 quadrants
Ellipses E–H (Figure 1) represent scenarios where
95% of the joint density (DC,DE) occupies two
quadrants, the resulting CEACs are illustrated in
Figure 3.
(E) The ellipse falls within the NE and SE
quadrants (more or less costly, more eﬀec-
tive). The CEAC does not cut the y-axis at 0
because some (here 50%) of the joint density
(DC,DE) involves cost-savings. The CEAC
asymptotes to 1 because the entire density
0 5000 10000
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
AC
B
D
Value of health effect 
Pr
ob
ab
ili
ty
 in
te
rv
en
tio
n 
is
 c
os
t-e
ffe
ct
iv
e
gi
ve
n 
th
e 
da
ta
λ
Figure 2. CEACs where there is a negligible probability that the joint density extends beyond a single quadrant of the CE plane:
scenarios A–D
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involves health gains. Hence, the CEAC is an
increasing function of l.
(F) The ellipse falls within the SE and SW
quadrants (less costly, more or less eﬀective).
The CEAC cuts the y-axis at 1 because the
entire density involves cost-savings. The
CEAC asymptotes to a value less than 1
because not all of the joint density involves
health gains (here only 50%). Hence, the
CEAC is a decreasing function of l.
(G) The ellipse falls within the SW and NW
quadrants (more or less costly, less eﬀective).
The CEAC does not cut the y-axis at 0
because some of the joint density involves
cost-savings (here 50%). The CEAC asymp-
totes to 0 because none of the density involves
health gains. Hence, the CEAC is a decreasing
function of l.
(H) The ellipse falls within the NE and NW
quadrants (more costly, more or less eﬀec-
tive). The CEAC cuts the y-axis at 0 because
none of the density involves cost-savings. The
CEAC asymptotes to a value less than 1
because not all of the density involves health
gains (here only 50%). Hence, the CEAC is an
increasing function of l.
Ellipses occupying all quadrants
Ellipses I–M (Figures 1, 4 and 5) represent
scenarios where substantial portions of the joint
density (DC,DE) cover all four quadrants of the
CE plane, the resulting CEACs are illustrated in
Figures 3 and 6.
(I) Scenario I (Figure 1) illustrates a special case
where the ellipse is centred upon the origin
(the intervention is expected to be exactly as
costly and eﬀective as the comparator) with
equal portions of the density falling into each
of the quadrants. The CEAC does not cut the
y-axis at 0 because some of the density
involves cost-savings. The CEAC does not
asymptote to 1 because not all of the density
involves health gains. Here the CEAC cuts
the y-axis at 0.5 because half of the joint
density lies in the SW and SE quadrants, and
asymptotes to 0.5 as only half of the joint
density lies in the NE and SE quadrants. For
this special case, an identical amount of the
density is included as cost-eﬀective (NE
quadrant) as is excluded as no longer cost-
eﬀective (SW quadrant) as l increases. As a
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Figure 3. CEACs when the joint density lies in two quadrants of the CE plane, and a special case of all four quadrants: scenarios
E–I
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Figure 4. Two cost-eﬀectiveness scenarios where the joint density covers all quadrants of the CE plane. Each example involves a
correlation of 0.5
-$40,000
-$30,000
-$20,000
-$10,000
$0
$10,000
$20,000
$30,000
$40,000
-20 -15 -10 -5 0 5 10 15 20
Incremental QALYs
In
cr
em
en
ta
l c
os
ts
L
M
NE
SE
NW
SW
Figure 5. Further two cost-eﬀectiveness scenarios where the joint density covers all quadrants of the CE plane. Each example
involves a correlation of +0.5
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result the CEAC forms a horizontal line
through 0.5 (Figure 3). This ‘bullseye’ sce-
nario is an extreme case that is unlikely to
occur in practice but which provides a useful
illustration of the principles of the CEAC.
(J) The ellipse falls within all of the quadrants,
with the majority contained within the NE
quadrant (more costly, more eﬀective). The
CEAC does not cut the y-axis at 0 because
some of the density involves cost-savings
(here 21%). The CEAC does not asymptote
to 1 because not all of the density involves
health gains (here only 88%).
(K) The ellipse falls within all of the quadrants,
with the majority contained within the SW
quadrant (less costly, less eﬀective). The
CEAC does not cut the y-axis at 0 because
some of the density involves cost-savings
(here 79%). The CEAC does not asymptote
to 1 because not all of the density involves
health gains (here only 12%). This scenario is
the inverse of scenario J.
(L) The ellipse falls within all of the quadrants,
with the majority contained within the NW
quadrant (more costly, less eﬀective). The
CEAC does not cut the y-axis at 0 because
some of the density involves cost-savings
(here 21%). The CEAC does not asymptote
to 1 because not all of the density involves
health gains (here only 11%). However, the
CEAC is not strictly a decreasing function of
l, due to the position of the joint density
(DC,DE) in the NE and SW quadrants. The
trade-oﬀ between cost and eﬀect implied by
the joint density (DC,DE) in the SW quad-
rant is lower than that implied by the joint
density (DC, DE) in the NE quadrant. Hence,
as l increases the joint density (DC,DE) in the
SW quadrant is excluded for no longer being
cost-eﬀective before the density in the NE
quadrant is included as cost-eﬀective, and the
CEAC falls before rising.
(M) The ellipse falls within all of the quadrants,
with the majority contained within the SE
quadrant (less costly, less eﬀective). The
CEAC does not cut the y-axis at 0 because
some of the density involves cost-savings
(here 79%). The CEAC does not asymptote
to 1 because not all of the density involves
health gains (here only 89%). However, the
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Figure 6. CEACs when the joint density covers all quadrants of the CE plane: scenarios J–M
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CEAC is not strictly an increasing function of
l, due to the position of the joint density
(DC,DE) in the NE and SW quadrants. The
trade-oﬀ between cost and eﬀect implied by
the joint density (DC,DE) in the SW quad-
rant is higher than that implied by the joint
density (DC, DE) in the NE quadrant. Hence,
as l increases the joint density in the NE
quadrant is included as cost-eﬀective before
the joint density in the SW quadrant is
excluded as no longer cost-eﬀective, and the
CEAC rises before falling. This scenario is
the inverse of scenario L.
Some additional issues with CEACS
Bayesian or frequentist interpretation of
CEACs?
Within this paper and more widely within the
literature CEACs have been interpreted as repre-
senting the ‘probability that the intervention is
cost-eﬀective’ given the data [26–30]. It has been
suggested that this interpretation is the most
natural and useful as it directly addresses the issue
of interest for decision-makers [26,31]. However,
this interpretation is only valid in a Bayesian
framework where parameters are taken to be
random variables with associated probability
distributions. Within the classical frequentist
approach, parameters are taken as ﬁxed, unvary-
ing quantities. As such there is no place, within
the frequentist approach, for attaching probabil-
ities to possible values of the parameter. Instead,
frequentist inference involves determining the
probability (p-value) of attaining the data
observed (or data more extreme than that ob-
served) given a hypothesis regarding the para-
meter. It has been shown that the p-value curve,
which plots the one-sided p-value on a test of
positive incremental net beneﬁt over a range of
values of l is the mirror image of the CEAC
[19,26,32,33]. The p-value curve intersects the y-
axis at one minus the one-sided p-value on a test of
diﬀerences between costs, and asymptotes to the
one-sided p-value on a test of diﬀerences between
eﬀectiveness [26,32]. However, the y-axis can only
be interpreted as the ‘probability that the inter-
vention is cost-eﬀective’ when a Bayesian analysis
incorporating a prior (vague or informative) has
been undertaken [26].
Joint signiﬁcance versus individual signiﬁcance
Any ellipse that crosses the x- or y-axis is
associated with a non-signiﬁcant diﬀerence in
costs (x-axis) and/or eﬀects (y-axis). However,
these scenarios may be associated with signiﬁcant
diﬀerences in cost-eﬀectiveness for some range of l
values. For example, in scenarios E, F, G, H, L
and M there are values of l for which 95% of the
joint density is considered cost-eﬀective (scenarios
E, F and M) or cost-ineﬀective (scenarios G, H
and L) despite the lack of individual signiﬁcance of
cost and/or eﬀect. However, note that this is not
the case for scenarios J and K where there are no
values of l for which 95% of the joint density is
cost-eﬀective/cost-ineﬀective.
CEACs and dominance
The CEAC does not provide an illustration of the
probability of dominance (determined by the
presence and proportion of the joint density
located within the SE quadrant) or the inverse,
the probability of being dominated (determined by
the presence and proportion of the joint density
located within the NW quadrant). These prob-
abilities are not presented on the curve as there is
no value of l for which these quadrants are
isolated. However, this information may be of
interest to the decision-maker and, hence, we
recommend that this information be reported
alongside the CEAC, either numerically or gra-
phically as additional lines on the ﬁgure (as in Van
Hout [18]).
The CEAC and value-of-information (VOI)
analysis
The CEAC is a device that allows a visual
impression of the joint uncertainty in the single
dimension of the decision space. In particular, the
CEAC overcomes the problems associated with
estimating conﬁdence intervals for cost-eﬀective-
ness ratios. A number of commentators have
argued that the objective of the health system is
to maximise health gain for limited resources and
that, given this objective, it is the expected value of
an intervention that is important for the immedi-
ate adoption decision [34,35]. As a consequence it
has been argued that inference, including ranges of
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equivalence and benchmark error probabilities, is
not useful or consistent with rational decision-
making [34].
Does this mean that uncertainty is not impor-
tant for decision-making and, by implication, that
CEACs are redundant? The answer is of course no.
Decision uncertainty aﬀects the expected value of
the decision (through the possibility that the
incorrect decision is made) and hence further
information, which reduces this uncertainty, has
value. Formal value-of-information (VOI) techni-
ques assess the expected costs of uncertainty
surrounding a decision made on the basis of
current information, in order to determine whether
further research should be conducted and how this
should be designed. The CEAC (or more precisely,
its complement) provides the probability that the
intervention of interest is not cost-eﬀective, i.e. the
probability that a decision to choose that inter-
vention is incorrect. It is this probability that is
combined with the loss function associated with
incorrect decision-making to give the VOI. Further
discussion of these issues, together with an
introduction to the concept of the cost-eﬀective-
ness acceptability frontier (CEAF) which shows
the portion of competing CEACs that have the
maximum expected value, are given in Fenwick
et al. [27]. In conclusion, the accurate assessment
of uncertainty is necessary, although not suﬃcient,
for a VOI analysis, suggesting a continuing role for
the CEAC as a step on the route determining if
there is value in conducting further research.
Conclusions
Through a series of cost-eﬀectiveness scenarios we
have illustrated some facts and fallacies about
CEACs. We have shown that:
(i) CEACs do not always cut the y-axis at 0.
(ii) CEACs do not always asymptote to 1.
(iii) CEACs are not always monotonically increas-
ing in l and as a consequence.
(iv) CEACs are not cumulative distribution func-
tions (see Appendix A).
When constructing and interpreting CEACs the
simple rules to remember are:
(i) Cost-savings and CEAC origins. The value at
which the CEAC crosses the y-axis is deter-
mined by the presence and proportion of the
joint density (DC,DE) within the southerly
quadrants (SW and/or SE).
(ii) Eﬀect gains and CEAC asymptotes. The value
to which the CEAC asymptotes is determined
by the presence and proportion of the joint
density (DC, DE) within the easterly quad-
rants (NE and/or SE).
(iii) Position and shape. The shape of the CEAC is
determined by the location and proportion of
the joint density (DC,DE) within each of the
quadrants.
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Notes
a. If the position of the intervention and control were
reversed the joint density would fall within the NE
quadrant.
Appendix A
A cumulative distribution function (cdf) reﬂects
the probability that a random variable X is below
a certain value x. It is the integral of the
probability density function (pdf) below x:
FðxÞ ¼ PðX5xÞ ¼
Z 1
1
xf ðxÞ dx
A cdf is non-decreasing (monotonically increas-
ing) in x, that is where
x1  x2 ) Fðx1Þ4Fðx2Þ
In addition
Lim
x!1
FðxÞ ¼ 0
and
Lim
x!1
FðxÞ ¼ 1
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Here, the random variable X represents the joint
density (DC,DE) and x represents the value of l.
As described above, the construction of CEACs
involves including the joint density (DC,DE) that
falls in the NE quadrant (DE > 0, DC > 0) as the
value of l increases, whilst simultaneously exclud-
ing the joint density (DC,DE) that falls in the SW
quadrant (where DE5 0 and DC5 0). Hence, the
CEAC is not non-decreasing in x – as l increases,
the probability that the joint density is below l
may rise or fall. In addition, it is not true that the
limit of the CEAC is 1 as l tends to inﬁnity. As
stated above this depends upon the location and
proportion of the joint density that falls within the
easterly quadrants (NE and/or SE). Hence, the
CEAC does not represent a cumulative density
function.
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